The kidney is a central hub of mammalian metabolism, but its metabolic function is relatively understudied. Recent data shows that changes in kidney proximal tubule transport and metabolism, such as inhibition of sugar transport, is an effective therapeutic strategy in patients with diabetic and non-diabetic kidney disease. In this project, we aim understand the mechanism by which common amino acid-sugar conjugates alter or propagate kidney disease. We will analyze rodent models, cell cultures and human material using targeted and untargeted metabolomics as well as functional assays. The overarching goal is to explore the handling and molecular wiring of sugar-amino acid conjugates in the proteo-metabolomic space of the kidney in an interdisciplinary fashion.
My research goal is to understand the mechanisms of kidney disease to develop new therapies for renal failure. To this end, he integrates mass spectrometry-based proteome and metabolome analyses to define the mechanisms that determine tissue fate and heterogeneity. Having trained in physiological, systems biology, nephrology and mass spectrometry labs, he is developing omics technologies that are directly applicable to investigate patient-relevant disease mechanisms from human biopsies, subproteomes and interactomes. He is a trained physician working in both Denmark and Germany.